Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMA1 | P23946 | 9/20 | 0.83 |
| ▸ | CTSG | P08311 | 2/20 | 0.83 |
| ▸ | CDK1 | P06493 | 5/20 | 0.41 |
| ▸ | GSK3B | P49841 | 6/20 | 0.36 |
| ▸ | CCNB2 | O95067 | 4/20 | 0.36 |
| ▸ | CCNB1 | P14635 | 4/20 | 0.36 |
| ▸ | CCNB3 | Q8WWL7 | 4/20 | 0.36 |
| ▸ | DRD2 | P14416 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | GSK3A | P49840 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2309855 | 0.91 | CMA1 (1.00) | CMA1CTSGCDK1GSK3BCCNB2 | |
| SCHEMBL12431684 | 0.90 | CMA1 (0.69) | CMA1CTSGCDK1GSK3BCCNB2 | |
| SCHEMBL2310839 | 0.81 | CMA1 (1.00) | CMA1CTSGSMN1; SMN2 | |
| SCHEMBL8118424 | 0.81 | CMA1 (0.54) | CMA1CTSGKDM4ESMN1; SMN2MEN1 | |
| SCHEMBL8105375 | 0.80 | CMA1 (0.62) | CMA1CTSGSMN1; SMN2MEN1KMT2A | |
| SCHEMBL2314701 | 0.79 | CMA1 (1.00) | CMA1CTSGCDK1GSK3BCCNB2 | |
| SCHEMBL12431674 | 0.75 | CMA1 (0.48) | CMA1CTSGKDM4ESMN1; SMN2MEN1 | |
| SCHEMBL13129768 | 0.75 | CMA1 (0.49) | CMA1CTSGCDK1GSK3BCCNB2 | |
| SCHEMBL8118350 | 0.75 | CMA1 (0.49) | CMA1CTSG | |
| SCHEMBL8122292 | 0.75 | CMA1 (0.86) | CMA1CTSGCDK1GSK3BCCNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9150556-B2 | Benzimidazolone chymase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-10-06 | — | — | US | disclosed |
| EP-2152674-B1 | BENZIMIDAZOLONE CHYMASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2011-08-03 | — | — | EP | disclosed |
| US-20100240702-A1 | Benzimidazolone Chymase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-23 | — | — | US | disclosed |
| EP-2152674-A1 | BENZIMIDAZOLONE CHYMASE INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2010-02-17 | — | — | EP | disclosed |
| WO-2008147697-A1 | BENZIMIDAZOLONE CHYMASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-12-04 | — | — | WO | disclosed |
| WO-2008147697-A1 | BENZIMIDAZOLONE CHYMASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240702-A1 | Benzimidazolone Chymase Inhibitors | CMA1, SERPINB1, CPA3 | CMA1 1/4885CTSG 26/4885CDK1 971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.